Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 4143 | 26.87 |
09:34 ET | 6747 | 27.14 |
09:36 ET | 700 | 27.07 |
09:38 ET | 2945 | 27.39 |
09:39 ET | 1650 | 27.39 |
09:41 ET | 725 | 27.33 |
09:43 ET | 1100 | 27.22 |
09:45 ET | 400 | 27.0991 |
09:48 ET | 3700 | 27.29 |
09:50 ET | 200 | 27.24 |
09:52 ET | 5028 | 27.105 |
09:56 ET | 4363 | 27.32 |
09:57 ET | 400 | 27.25 |
09:59 ET | 800 | 27.35 |
10:01 ET | 1745 | 27.28 |
10:03 ET | 1300 | 27.25 |
10:06 ET | 11142 | 27.245 |
10:08 ET | 1979 | 27.26 |
10:10 ET | 1300 | 27.225 |
10:12 ET | 400 | 27.28 |
10:14 ET | 700 | 27.27 |
10:15 ET | 6237 | 27.254 |
10:17 ET | 200 | 27.23 |
10:19 ET | 4196 | 27.27 |
10:21 ET | 1585 | 27.31 |
10:24 ET | 2476 | 27.31 |
10:26 ET | 1457 | 27.36 |
10:28 ET | 1394 | 27.29 |
10:30 ET | 1355 | 27.27 |
10:32 ET | 1666 | 27.26 |
10:33 ET | 2423 | 27.3 |
10:35 ET | 277 | 27.3 |
10:37 ET | 7440 | 27.23 |
10:39 ET | 1000 | 27.29 |
10:42 ET | 1592 | 27.29 |
10:44 ET | 800 | 27.27 |
10:46 ET | 1623 | 27.26 |
10:48 ET | 1100 | 27.26 |
10:50 ET | 534 | 27.26 |
10:51 ET | 900 | 27.26 |
10:53 ET | 1600 | 27.31 |
10:55 ET | 4960 | 27.335 |
10:57 ET | 1879 | 27.335 |
11:00 ET | 633 | 27.32 |
11:02 ET | 2767 | 27.32 |
11:04 ET | 2100 | 27.22 |
11:08 ET | 777 | 27.095 |
11:09 ET | 636 | 27.095 |
11:11 ET | 100 | 27.06 |
11:13 ET | 1800 | 26.94 |
11:15 ET | 1300 | 26.97 |
11:20 ET | 700 | 26.95 |
11:22 ET | 454 | 26.93 |
11:24 ET | 2106 | 26.9 |
11:26 ET | 936 | 26.9 |
11:27 ET | 4024 | 26.96 |
11:31 ET | 100 | 26.98 |
11:33 ET | 2618 | 26.92 |
11:36 ET | 721 | 26.91 |
11:38 ET | 610 | 26.93 |
11:40 ET | 2089 | 26.855 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.9B | -14.2x | --- |
Avidity Biosciences Inc | 4.1B | -12.9x | --- |
Immunitybio Inc | 4.4B | -6.3x | --- |
Crinetics Pharmaceuticals Inc | 3.5B | -11.8x | --- |
Dyne Therapeutics Inc | 3.4B | -8.6x | --- |
Merus NV | 3.6B | -20.3x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -14.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.